New conference focused on AI, cancer care to debut in Boston

Elsevier has launched a new healthcare conference dedicated to how AI and other advanced technologies can help improve cancer care for patients all over the world.

The conference, AI and Big Data in Caner: From Innovation to Impact, will occur March 29-31 in Boston. Representatives from the U.S. National Cancer Institute, DARPA, MIT, Harvard Business School, Google Health, Amazon Web Services and many other industry leaders are scheduled to speak. Presentations will cover such topics as the development and implementation of AI, building trust among customers and advancing innovation-friendly policies.

“It is time to shift our conversation from ‘what-technology-can-do’ to ‘what-medicine-needs’ and to raise awareness of what else is necessary to translate an AI-enabled and data-driven innovation into a marketed product,” Lynda Chin, MD, conference chair and founder and CEO of Apricity Health, said in a prepared statement. “Understanding what these hurdles are is the first step to overcoming them.”

“Insights from the program's 40 key opinion leaders will advance the emerging digital medicine industry, building bridges from computer to clinics,” said Laura Colantoni, Elsevier’s vice president for reference content and a conference organizer, said in the same statement. “We are particularly excited about establishing this conference as a venue for successful innovators, influential facilitators, regulators and payers, as well as investors to find, engage and collaborate with clinicians, researchers and patients to accelerate progress in this area. We believe this to be an amazing networking opportunity for all stakeholders in the digital medicine industry and those interested in this whole field.”

More information on the conference is available here.

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.